R&D | 12 October 2026
Lonza and Onava team up to accelerate AI-native biologics discovery
GS Ori-Go vectors will support faster transition from computational prediction to experimental validation
GS Ori-Go vectors will support faster transition from computational prediction to experimental validation
CERVAVAC targets HPV types 6, 11, 16 and 18 and is indicated for both girls and boys aged 9 to 26 years.
Himalaya will advance a standardized herbal extract developed by CSIR-CDRI scientists T Narender and Rajesh Jha for its potential application in PMOS
Supporting high-performance 3D model construction and high-precision, high-throughput efficacy evaluation
The hub will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicines
This international patent grant strengthens the company's global intellectual property (IP) portfolio
The study evaluated the effectiveness, durability and safety of Vabysmo (faricimab) in neovascular age-related macular degeneration
The analysis found that people taking Zepbound (tirzepatide) 15 mg lost an average of 4.5% more body weight than those taking Wegovy HD (semaglutide 7.2 mg) after 72 weeks
SB HiMax helps biotechs facing compressed development timelines but struggling to find partners with the speed and flexibility
The collaboration will also support the development of a ‘Professor of Practice’ framework
The pharmaceutical giant said 11 of the presentations will be oral sessions at the October 23-27 ESMO Congress in Madrid
This is the most comprehensive, population-scale, molecular mapping of Alzheimer’s and related neurodegenerative and neuropsychiatric disorders to date
Novel antenna design could enable non-invasive sensing of tissue abnormalities; researchers are currently advancing the simulation model towards prototype development
Prof. Sood emphasized how BRICS+ cooperation serves as a vital catalyst for driving global medical technology innovation and addressing shared healthcare challenges
The partnership will apply Iambic’s AI platform across immunology, neuroscience and oncology
Review highlights why getting medicines into the brain is only the first step
Dose formulation, drug-drug interaction risk and evidence of long-term response followed as additional factors influencing treatment choices
The companies will work together on key drug discovery challenges identified by Novo’s scientists and computational teams
The companies have signed a research collaboration and license agreement to advance MDL-201, an innovative therapeutic candidate for DMD
Subscribe To Our Newsletter & Stay Updated
